Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BMS131-2FI - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-IL-10 Monoclonal Antibody (BT-10), FITC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: IL-10 (BT-10) is a mouse monoclonal antibody raised against IL-10 of human origin. BMS 131/2 is recommended for detection of IL-10 of human origin by solid phase ELISA. Interleukin-10 is a regulator of lymphoid and myeloid cell function. In humans IL-10 is produced by activated CD8(+) peripheral blood T-cells, by T-helper CD4(+) T-cell clones. Due to the ability of IL-10 to block cytokine synthesis and several accessory cell functions of macrophages this cytokine is a potent suppressor of the effector functions of macrophages, T-cells and NK cells. In addition, IL-10 participates in regulating proliferation and differentiation of B-cells, mast cells and thymocytes. The corresponding protein exerts 160 amino acids with a predicted molecular mass of 18.5 kDa. Based on its primary structure, IL-10 is a member of the four a-helix bundle family of cytokines. In solution human IL-10 is a homodimer with an apparent molecular mass of 39 kDa. Although it contains an N-linked, glycosylation site, it lacks detectable carbohydrates. The immunosuppressive properties of IL-10 suggest a possible clinical use of IL-10 in suppressing rejections of grafts after organ transplantations. IL-10 can furthermore exert strong anti-inflammatory activities. Purity is greater than 95% IgG1 as determined by SDS-PAGE.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Green dye
- Isotype
- IgG
- Antibody clone number
- BT-10
- Vial size
- 100 Tests
- Concentration
- 0.1 mg/mL
- Storage
- 4° C
Submitted references Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients.
Abd Al Samid M, Chaudhary B, Khaled YS, Ammori BJ, Elkord E
Oncotarget 2016 Mar 22;7(12):14083-94
Oncotarget 2016 Mar 22;7(12):14083-94
No comments: Submit comment
No validations: Submit validation data